|
US6962792B1
(en)
|
1996-05-08 |
2005-11-08 |
Cyclacel Limited |
Methods and means for inhibition of Cdk4 activity
|
|
BR0116662A
(pt)
|
2001-01-02 |
2003-09-23 |
Hoffmann La Roche |
Derivados de quinazolona como antagonistas receptores alfa 1a/b adrenérgicos
|
|
US7105667B2
(en)
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
|
WO2002088079A2
(en)
|
2001-05-01 |
2002-11-07 |
Bristol-Myers Squibb Company |
Dual inhibitors of pde 7 and pde 4
|
|
US7915301B2
(en)
|
2002-07-08 |
2011-03-29 |
Piramal Life Science Limited |
Inhibitors of cyclin dependent kinases and their use
|
|
AU2005264213A1
(en)
|
2004-05-21 |
2006-01-26 |
Msd K.K. |
Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton
|
|
ES2349476T3
(es)
|
2005-09-09 |
2011-01-03 |
Schering Corporation |
Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina.
|
|
US20080051387A1
(en)
|
2006-06-09 |
2008-02-28 |
Yuelian Xu |
Tetrahydropyrido[3,4-d]pyrimidines and related analogues
|
|
WO2008009078A2
(en)
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
|
AU2007336781C1
(en)
|
2006-12-21 |
2014-10-09 |
Sloan-Kettering Institute For Cancer Research |
Pyridazinones and furan-containing compounds
|
|
WO2008103470A2
(en)
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
WO2009034411A1
(en)
|
2007-09-12 |
2009-03-19 |
Centre National De La Recherche Scientifique |
Perharidines as cdk inhibitors
|
|
EP2209775A1
(en)
|
2007-10-09 |
2010-07-28 |
UCB Pharma, S.A. |
Heterobicyclic compounds as histamine h4-receptor antagonists
|
|
US9259399B2
(en)
|
2007-11-07 |
2016-02-16 |
Cornell University |
Targeting CDK4 and CDK6 in cancer therapy
|
|
CA2729045A1
(en)
|
2008-07-31 |
2010-02-04 |
Philippe Bergeron |
Pyrimidine compounds, compositions and methods of use
|
|
EP2179992A1
(de)
|
2008-10-21 |
2010-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
EP2179991A1
(de)
|
2008-10-21 |
2010-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
WO2010058006A1
(en)
|
2008-11-24 |
2010-05-27 |
Nerviano Medical Sciences S.R.L. |
Cdk inhibitor for the treatment of mesothelioma
|
|
WO2010075542A1
(en)
|
2008-12-23 |
2010-07-01 |
Curis, Inc. |
Cdk inhibitors
|
|
WO2010120996A1
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
EP2421848A1
(en)
|
2009-04-22 |
2012-02-29 |
Janssen Pharmaceutica N.V. |
Azetidinyl diamides as monoacylglycerol lipase inhibitors
|
|
US20120100100A1
(en)
|
2009-05-13 |
2012-04-26 |
Sharpless Norman E |
Cyclin dependent kinase inhibitors and methods of use
|
|
CA2785284A1
(en)
|
2009-12-25 |
2011-06-30 |
Tomoyuki Kamino |
Novel aryl urea derivative
|
|
KR20130067487A
(ko)
|
2009-12-30 |
2013-06-25 |
아빌라 테라퓨틱스, 인크. |
단백질의 리간드-지정 공유 변형
|
|
KR101180030B1
(ko)
|
2010-02-05 |
2012-09-05 |
광주과학기술원 |
사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체
|
|
ES2689177T3
(es)
*
|
2010-04-13 |
2018-11-08 |
Novartis Ag |
Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
|
|
US8566072B2
(en)
|
2010-04-16 |
2013-10-22 |
University Of South Carolina |
Cyclin based inhibitors of CDK2 and CDK4
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
MX379532B
(es)
|
2010-10-25 |
2025-03-10 |
G1 Therapeutics Inc |
Inhibidores de cdk.
|
|
US9062088B2
(en)
|
2010-11-02 |
2015-06-23 |
Snu R&Db Foundation |
CDK-inhibiting pyrrolopyrimidine carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing the same as active ingredient for preventing or treating hepatocellular carcinoma
|
|
US8551992B2
(en)
|
2011-05-27 |
2013-10-08 |
Neosome Life Sciences, LLC |
Aminooxazole inhibitors of cyclin dependent kinases
|
|
US20140296484A1
(en)
|
2013-03-27 |
2014-10-02 |
University Of South Carolina |
Cyclin Based Inhibitors of CDK2 and CDK4
|
|
US20130289240A1
(en)
|
2012-03-27 |
2013-10-31 |
Campbell McInnes |
Cyclin Based Inhibitors of CDK2 and CDK4
|
|
US9376465B2
(en)
|
2012-03-27 |
2016-06-28 |
University Of South Carolina |
Cyclin based inhibitors of CDK2 and CDK4
|
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
US9695133B2
(en)
|
2012-07-13 |
2017-07-04 |
The Trustees Of Columbia University In The City Of New York |
Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
|
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
|
TW201524952A
(zh)
|
2013-03-15 |
2015-07-01 |
Araxes Pharma Llc |
Ｋｒａｓ ｇ１２ｃ之共價抑制劑
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
CN106488910B
(zh)
|
2013-10-10 |
2020-07-31 |
亚瑞克西斯制药公司 |
Kras g12c的抑制剂
|
|
EP3148981A4
(en)
|
2014-05-30 |
2017-11-08 |
The Trustees of Columbia University in the City of New York |
Multivalent ras binding compounds
|
|
AU2015292425B2
(en)
|
2014-07-24 |
2018-12-20 |
Beta Pharma, Inc. |
2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof
|
|
WO2016025650A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
|
WO2016049565A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions and methods for inhibition of ras
|
|
EP3197870B1
(en)
|
2014-09-25 |
2020-08-19 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10017540B2
(en)
|
2015-03-11 |
2018-07-10 |
California Institute Of Technology |
Cyclic peptide binder against oncogenic K-Ras
|
|
EP3280708B1
(en)
|
2015-04-10 |
2021-09-01 |
Araxes Pharma LLC |
Substituted quinazoline compounds and methods of use thereof
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
US10421764B2
(en)
|
2015-04-24 |
2019-09-24 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Mutant KRas inhibitors
|
|
US10857140B2
(en)
|
2015-05-06 |
2020-12-08 |
The Regents Of The University Of California |
K-Ras modulators
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
CN108513588A
(zh)
|
2015-09-24 |
2018-09-07 |
Ionis制药公司 |
Kras表达的调节剂
|
|
EP3356339A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058792A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3364977A4
(en)
|
2015-10-19 |
2019-09-04 |
Araxes Pharma LLC |
PROCESS FOR SCREENING INHIBITORS OF RAS
|
|
CA3001847A1
(en)
|
2015-10-22 |
2017-04-27 |
The Scripps Research Institute |
Cysteine reactive probes and uses thereof
|
|
WO2017080980A1
(en)
|
2015-11-09 |
2017-05-18 |
Astrazeneca Ab |
Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
|
|
WO2017079864A1
(en)
|
2015-11-12 |
2017-05-18 |
Hangzhou Yier Biotech Co., Ltd. |
Treatment of cancers related to chronically active ras
|
|
EA038635B9
(ru)
|
2015-11-16 |
2021-10-26 |
Араксис Фарма Ллк |
2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
|
|
US20170157212A1
(en)
|
2015-12-03 |
2017-06-08 |
Salk Institute For Biological Studies |
Cdk modulators and methods for the treatment of cancer
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
US20170283445A1
(en)
|
2016-04-05 |
2017-10-05 |
University Of South Carolina |
Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
|
|
EP3458445B1
(en)
*
|
2016-05-18 |
2021-02-17 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
EP3519402A1
(en)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
BR112019011035A2
(pt)
|
2016-11-30 |
2019-10-15 |
Bantam Pharmaceutical Llc |
métodos de uso de compostos pirazol e pirazol substituído e para o tratamento de doenças hiperproliferativas
|
|
AU2017366901B2
(en)
|
2016-11-30 |
2022-09-29 |
Bantam Pharmaceutical, Llc |
Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
|
|
KR20190095355A
(ko)
|
2016-12-15 |
2019-08-14 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암의 치료를 위한 조성물 및 방법
|
|
EP3878850A1
(en)
|
2016-12-22 |
2021-09-15 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
|
MY196830A
(en)
*
|
2016-12-22 |
2023-05-03 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
US10344026B2
(en)
|
2017-01-18 |
2019-07-09 |
Nantbio, Inc. |
Compositions and methods of targeting mutant K-ras
|
|
EP3573967A1
(en)
*
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11279689B2
(en)
|
2017-01-26 |
2022-03-22 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
|
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US20200385364A1
(en)
|
2017-01-26 |
2020-12-10 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
AU2018255413A1
(en)
|
2017-04-20 |
2019-12-05 |
Leidos Biomedical Research, Inc. |
K-Ras modulators
|
|
AR112797A1
(es)
|
2017-09-08 |
2019-12-11 |
Amgen Inc |
Inhibidores de kras g12c y métodos para utilizarlos
|
|
EP3710439B1
(en)
|
2017-11-15 |
2023-02-15 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
EP3832583A4
(en)
|
2018-07-31 |
2021-12-08 |
Honda Motor Co., Ltd. |
ENERGY PREDICTION SYSTEM, ENERGY PREDICTION DEVICE, ENERGY PREDICTION METHOD, STORAGE PROGRAM AND MEDIA
|
|
CN113038342B
(zh)
|
2018-09-30 |
2022-10-14 |
荣耀终端有限公司 |
音频播放电路和终端
|
|
CN111193490B
(zh)
|
2018-11-14 |
2025-05-13 |
天津大学 |
散热结构、带散热结构的体声波谐振器、滤波器和电子设备
|
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
US20220193242A1
(en)
|
2019-02-07 |
2022-06-23 |
The Regents Of The University Of California |
Immunophilin-dependent inhibitors and uses thereof
|
|
WO2020165670A1
(en)
|
2019-02-11 |
2020-08-20 |
Mesomat Inc. |
Sensing fibers for structural strain monitoring
|
|
KR102747104B1
(ko)
|
2019-02-18 |
2024-12-27 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
|
|
GB2613715B
(en)
|
2019-02-20 |
2023-12-06 |
Fred Hutchinson Cancer Center |
Binding proteins specific for RAS neoantigens and uses thereof
|
|
GB201902392D0
(en)
|
2019-02-21 |
2019-04-10 |
Cambridge Entpr Ltd |
Modular binding proteins
|
|
EP3931564A4
(en)
|
2019-02-26 |
2023-04-26 |
Cell Response, Inc. |
Methods for treating map3k8 positive cancers
|
|
WO2020177629A1
(zh)
|
2019-03-01 |
2020-09-10 |
劲方医药科技(上海)有限公司 |
螺环取代的嘧啶并环类化合物，其制法与医药上的用途
|
|
AU2019432235B2
(en)
|
2019-03-05 |
2024-02-01 |
Questor Technology Inc. |
Gas incinerator system
|
|
WO2020178282A1
(en)
|
2019-03-05 |
2020-09-10 |
Astrazeneca Ab |
Fused tricyclic compounds useful as anticancer agents
|
|
EP3941938A1
(en)
|
2019-03-06 |
2022-01-26 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
|
US20220160714A1
(en)
|
2019-03-22 |
2022-05-26 |
Icahn School Of Medicine At Mount Sinai |
Methods for treating colorectal cancer
|
|
CA3134825A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
AU2020253823A1
(en)
|
2019-03-29 |
2021-10-14 |
Dicerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of KRAS associated diseases or disorders
|
|
KR102222693B1
(ko)
|
2019-04-04 |
2021-03-04 |
금정제약 주식회사 |
H-rev107 유래 펩타이드의 신규한 용도
|
|
US20220227740A1
(en)
|
2019-04-15 |
2022-07-21 |
Tosk, Inc. |
Modulators of RAS GTPase
|
|
US20200335182A1
(en)
|
2019-04-16 |
2020-10-22 |
Uratim Ltd. |
Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions
|
|
WO2020221239A1
(zh)
|
2019-04-28 |
2020-11-05 |
劲方医药科技(上海)有限公司 |
氧杂氮杂喹唑啉-7(8h)-酮类化合物，其制法与医药上的用途
|
|
PT3966206T
(pt)
|
2019-05-10 |
2023-11-10 |
Deciphera Pharmaceuticals Llc |
Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de utilização dos mesmos
|
|
US11530206B2
(en)
|
2019-05-10 |
2022-12-20 |
Deciphera Pharmaceuticals, Llc |
Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
EP3969449B1
(en)
|
2019-05-13 |
2025-02-12 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
WO2020230091A1
(en)
|
2019-05-14 |
2020-11-19 |
Janssen Biotech, Inc. |
Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
|
|
JP7502337B2
(ja)
|
2019-05-20 |
2024-06-18 |
カリフォルニア インスティチュート オブ テクノロジー |
Ｋｒａｓ ｇ１２ｃインヒビター及びその使用
|
|
MX2021014096A
(es)
|
2019-05-21 |
2022-02-11 |
Inventisbio Co Ltd |
Compuestos heterociclicos, metodos de preparacion y usos de estos.
|
|
WO2020234103A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
|
US12252486B2
(en)
|
2019-05-21 |
2025-03-18 |
Amgen Inc. |
Solid state forms
|
|
CA3225293A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
|
US20220306688A1
(en)
|
2019-06-07 |
2022-09-29 |
Emory University |
KRAS G12V Mutant Binds to JAK1, Inhibitors, Pharmaceutical Compositions, and Methods Related Thereto
|
|
AU2020291936A1
(en)
|
2019-06-12 |
2022-02-03 |
Vanderbilt University |
Dibenzylamines as amino acid transport inhibitors
|
|
AU2020291464A1
(en)
|
2019-06-12 |
2022-02-03 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
|
CN114040914B
(zh)
|
2019-07-01 |
2024-10-22 |
江苏恒瑞医药股份有限公司 |
喹唑啉酮类衍生物、其制备方法及其在医药上的应用
|
|
EP4011886A4
(en)
|
2019-08-02 |
2023-07-26 |
Shanghai Jemincare Pharmaceuticals Co., Ltd. |
TETRACYCLIC COMPOUND, METHOD FOR PREPARATION AND USE
|
|
WO2021023247A1
(en)
|
2019-08-07 |
2021-02-11 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitor
|
|
WO2021027943A1
(zh)
|
2019-08-14 |
2021-02-18 |
正大天晴药业集团南京顺欣制药有限公司 |
哒嗪酮并嘧啶类衍生物及其医药用途
|
|
CN112390797A
(zh)
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
|
US20220363681A1
(en)
|
2019-08-16 |
2022-11-17 |
Genfleet Therapeutics (Shanghai) Inc. |
Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
|
|
CA3150759A1
(en)
|
2019-08-22 |
2021-02-25 |
The Regents Of The Universtiy Of Michigan |
Method of treating kras-associated cancers
|
|
CN114269735B
(zh)
|
2019-08-26 |
2024-02-23 |
南京创济生物医药有限公司 |
二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
|
|
JP7622043B2
(ja)
|
2019-08-29 |
2025-01-27 |
ミラティ セラピューティクス， インコーポレイテッド |
Ｋｒａｓ ｇ１２ｄ阻害剤
|
|
US20230172914A1
(en)
|
2019-09-06 |
2023-06-08 |
Wellmarker Bio Co., Ltd. |
Biomarker-based therapeutic composition
|
|
CN114616232A
(zh)
|
2019-09-06 |
2022-06-10 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
|
US20220331401A1
(en)
|
2019-09-10 |
2022-10-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating kras mutant cancers
|
|
US20230002371A1
(en)
|
2019-09-13 |
2023-01-05 |
Biotheryx, Inc. |
Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
EP4031542B1
(en)
|
2019-09-18 |
2025-10-15 |
Merck Sharp & Dohme LLC |
Small molecule inhibitors of kras g12c mutant
|
|
CN116947885A
(zh)
|
2019-09-20 |
2023-10-27 |
上海济煜医药科技有限公司 |
稠合吡啶酮类化合物及其制备方法和应用
|
|
WO2021061515A1
(en)
|
2019-09-23 |
2021-04-01 |
Synblia Therapeutics, Inc. |
Shp2 inhibitors and uses thereof
|
|
CN114761012B
(zh)
|
2019-09-24 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
CN112552295A
(zh)
|
2019-09-25 |
2021-03-26 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
|
CN114929706A
(zh)
|
2019-09-29 |
2022-08-19 |
百济神州有限公司 |
Kras g12c的抑制剂
|
|
WO2021063346A1
(zh)
|
2019-09-30 |
2021-04-08 |
上海迪诺医药科技有限公司 |
Kras g12c抑制剂及其应用
|
|
CN114555586B
(zh)
|
2019-10-10 |
2023-06-23 |
信达生物制药(苏州)有限公司 |
Krasg12c蛋白抑制剂及其制备方法和用途
|
|
WO2021076655A1
(en)
|
2019-10-15 |
2021-04-22 |
Amgen Inc. |
Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
|
|
JP6754125B1
(ja)
|
2019-10-15 |
2020-09-09 |
学校法人東京理科大学 |
Ｂｒａｐ２作用増強剤
|
|
CN112694475B
(zh)
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
CA3154841A1
(en)
|
2019-10-23 |
2021-04-29 |
Yong Je Shin |
Bicyclic compound and use thereof
|
|
EP4048671A1
(en)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
PE20221253A1
(es)
|
2019-10-28 |
2022-08-16 |
Merck Sharp & Dohme |
Inhibidores de pequenas moleculas de mutante g12c de kras
|
|
CA3156777A1
(en)
|
2019-10-30 |
2021-05-06 |
Fusheng ZHOU |
Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof
|
|
WO2021084765A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd |
4-aminobut-2-enamide derivatives and salts thereof
|
|
CN115551500A
(zh)
|
2019-10-31 |
2022-12-30 |
大鹏药品工业株式会社 |
4-氨基丁-2-烯酰胺衍生物及其盐
|
|
WO2021088458A1
(en)
|
2019-11-04 |
2021-05-14 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitor
|
|
CA3160142A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2021091967A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN115894606A
(zh)
|
2019-11-04 |
2023-04-04 |
锐新医药公司 |
Ras抑制剂
|
|
SG10202111127YA
(en)
|
2019-11-07 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Cyclic Peptide Compound Having Kras Inhibitory Action
|
|
CN112778301A
(zh)
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
|
WO2021093758A1
(zh)
|
2019-11-15 |
2021-05-20 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
US12479834B2
(en)
|
2019-11-29 |
2025-11-25 |
Taiho Pharmaceutical Co., Ltd. |
Phenol compound or salt thereof
|
|
CN113614080B
(zh)
|
2019-11-29 |
2022-06-28 |
苏州信诺维医药科技股份有限公司 |
Kras g12c抑制剂化合物及其用途
|
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
BR112022010254A2
(pt)
|
2019-12-02 |
2022-09-06 |
Shanghai Yingli Pharm Co Ltd |
Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
|
|
WO2021113595A1
(en)
|
2019-12-06 |
2021-06-10 |
Beta Pharma, Inc. |
Phosphorus derivatives as kras inhibitors
|
|
US12365706B2
(en)
|
2019-12-18 |
2025-07-22 |
Merck Sharp & Dohme Llc |
Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant
|
|
WO2021120045A1
(en)
|
2019-12-18 |
2021-06-24 |
InventisBio Co., Ltd. |
Heterocyclic compounds, preparation methods and uses thereof
|
|
KR20220119088A
(ko)
|
2019-12-19 |
2022-08-26 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Kras 돌연변이체 단백질 억제제
|
|
WO2021121397A1
(zh)
|
2019-12-19 |
2021-06-24 |
首药控股(北京)股份有限公司 |
取代的炔基杂环化合物
|
|
WO2021121371A1
(zh)
|
2019-12-19 |
2021-06-24 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
|
TR201920922A2
(tr)
|
2019-12-20 |
2020-06-22 |
Ankara Ueniversitesi |
3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler
|
|
AU2020408562A1
(en)
|
2019-12-20 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2021129820A1
(zh)
|
2019-12-27 |
2021-07-01 |
微境生物医药科技(上海)有限公司 |
含螺环的喹唑啉化合物
|
|
CN113045565A
(zh)
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
WO2021139678A1
(zh)
|
2020-01-07 |
2021-07-15 |
广州百霆医药科技有限公司 |
吡啶并嘧啶类kras g12c突变蛋白抑制剂
|
|
TWI770760B
(zh)
|
2020-01-08 |
2022-07-11 |
大陸商蘇州亞盛藥業有限公司 |
螺環四氫喹唑啉
|
|
IL294526B1
(en)
|
2020-01-10 |
2025-10-01 |
Incyte Corp |
Tricyclic compounds as KRAS inhibitors
|
|
WO2021143693A1
(zh)
|
2020-01-13 |
2021-07-22 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
|
KR102396930B1
(ko)
|
2020-01-15 |
2022-05-12 |
한국과학기술연구원 |
피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
|
|
KR102382613B1
(ko)
|
2020-01-15 |
2022-04-06 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물
|
|
US11530218B2
(en)
|
2020-01-20 |
2022-12-20 |
Incyte Corporation |
Spiro compounds as inhibitors of KRAS
|
|
CN115003668A
(zh)
|
2020-01-21 |
2022-09-02 |
南京明德新药研发有限公司 |
作为kras抑制剂的大环类化合物
|
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
WO2021168193A1
(en)
|
2020-02-20 |
2021-08-26 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as kras inhibitors
|
|
JP7462985B2
(ja)
|
2020-02-24 |
2024-04-08 |
上海▲テツ▼▲ギョウ▼生物科技有限公司 |
芳香族化合物および抗腫瘍薬物の調製におけるその使用
|
|
CN113637005B
(zh)
|
2020-02-24 |
2024-05-24 |
泰励生物科技（上海）有限公司 |
用于癌症治疗的kras抑制剂
|
|
WO2021173923A1
(en)
|
2020-02-28 |
2021-09-02 |
Erasca, Inc. |
Pyrrolidine-fused heterocycles
|
|
CN114901663B
(zh)
|
2020-03-02 |
2024-07-02 |
上海喆邺生物科技有限公司 |
一类芳香杂环类化合物及其在药物中的应用
|
|
JP2023516381A
(ja)
|
2020-03-03 |
2023-04-19 |
ウェルマーカー・バイオ・カンパニー・リミテッド |
Ｋｒａｓ変異および活性化ｒｏｎが存在する癌の予防または治療のための医薬組成物
|
|
WO2021178741A1
(en)
|
2020-03-05 |
2021-09-10 |
The Regents Of The University Of Michigan |
Inhibitors of egfr, kras, braf, and other targets and use of the same
|
|
KR20250026883A
(ko)
|
2020-03-12 |
2025-02-25 |
디3 바이오 (우씨) 컴퍼니, 리미티드 |
피리미도헤테로사이클릭 화합물 및 이의 응용
|
|
WO2021185233A1
(en)
|
2020-03-17 |
2021-09-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
|
EP4129997A4
(en)
|
2020-04-03 |
2024-01-24 |
Medshine Discovery Inc. |
OCTAHYDROPYRAZINODIAZANAPHTHYRIDINDIONE COMPOUNDS
|
|
US20220370416A1
(en)
|
2020-04-06 |
2022-11-24 |
Arvinas Operations, Inc. |
Compounds and methods for targeted degradation of kras
|
|
WO2021203768A1
(zh)
|
2020-04-08 |
2021-10-14 |
江苏恒瑞医药股份有限公司 |
嘧啶并二环类衍生物、其制备方法及其在医药上的应用
|
|
IL297165A
(en)
|
2020-04-16 |
2022-12-01 |
Incyte Corp |
Soysag tricyclic CRS inhibitors
|
|
WO2021216770A1
(en)
|
2020-04-22 |
2021-10-28 |
Accutar Biotechnology Inc. |
Substituted tetrahydroquinazoline compounds as kras inhibitors
|
|
EP4138875A4
(en)
|
2020-04-23 |
2024-08-28 |
The Regents of the University of California |
RAS INHIBITORS AND USES THEREOF
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
KR20230019101A
(ko)
|
2020-04-29 |
2023-02-07 |
상하이 린진 바이오파마 씨오., 엘티디. |
벤조티아졸릴 비아릴 화합물, 제조 방법 및 용도
|
|
CN116194456B
(zh)
|
2020-04-30 |
2025-08-29 |
上海科州药物股份有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
CN113666923A
(zh)
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
|
WO2021236475A1
(en)
|
2020-05-18 |
2021-11-25 |
Asinex Corporation |
Compounds that inhibit asparagine synthetase and their methods of use
|
|
TWI799871B
(zh)
|
2020-05-27 |
2023-04-21 |
大陸商勁方醫藥科技(上海)有限公司 |
三環并環類化合物，其製法與醫藥上的用途
|
|
US20230212164A1
(en)
|
2020-06-02 |
2023-07-06 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
JP2023529354A
(ja)
|
2020-06-04 |
2023-07-10 |
ピライ ユニバーサル エルエルシー |
癌治療における標的化不能ｋｒａの標的分解のための新規の小分子
|
|
KR20230019855A
(ko)
|
2020-06-04 |
2023-02-09 |
안텐진 디스커버리 리미티드 |
Kras g12c 단백질의 억제제 및 그의 용도
|
|
WO2021248083A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248079A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
US20230023009A1
(en)
|
2020-06-05 |
2023-01-26 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248082A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
US20230026856A1
(en)
|
2020-06-05 |
2023-01-26 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021252339A1
(en)
|
2020-06-08 |
2021-12-16 |
Accutar Biotechnology, Inc. |
Substituted purine-2,6-dione compounds as kras inhibitors
|
|
WO2021249563A1
(zh)
|
2020-06-12 |
2021-12-16 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2021259331A1
(zh)
|
2020-06-24 |
2021-12-30 |
南京明德新药研发有限公司 |
八元含n杂环类化合物
|
|
EP4175947A4
(en)
|
2020-06-30 |
2024-07-03 |
InventisBio Co., Ltd. |
QUINAZOLINE COMPOUNDS, THEIR PREPARATION PROCESSES AND THEIR USES
|
|
EP4182313A4
(en)
|
2020-07-16 |
2024-10-09 |
Mirati Therapeutics, Inc. |
KRAS-G12D INHIBITORS
|
|
WO2022017339A1
(zh)
|
2020-07-20 |
2022-01-27 |
江苏恒瑞医药股份有限公司 |
稠合哒嗪类衍生物、其制备方法及其在医药上的应用
|
|
JP7584815B2
(ja)
|
2020-08-02 |
2024-11-18 |
上▲海▼▲哲▼▲イェ▼生物科技有限公司 |
抗腫瘍薬物における芳香族化合物及びその用途
|
|
WO2022031678A1
(en)
|
2020-08-04 |
2022-02-10 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
US20230322788A1
(en)
|
2020-08-05 |
2023-10-12 |
Beigene, Ltd. |
Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors
|
|
WO2022036176A1
(en)
|
2020-08-13 |
2022-02-17 |
Albert Einstein College Of Medicine |
N-cyclyl-sulfonamides useful for inhibiting raf
|